Co můžeme očekávat od léčby venetoklax + azacitidin (Ven + Aza) u pacientů s akutní myeloidní leukémii (AML): Výsledky studie VIALE-A a posthoc analýz.

Lubomír Minařík

What can we expect from venetoclax + azacitidine (Ven + Aza) treatment in patients with acute myeloid leukemia (AML): Results from the VIALE-A study and post-hoc analyses.

Authors

Lubomír Minařík I. interní klinika – klinika hematologie, Všeobecná fakultní nemocnice Praha

Abstract

In 2025, the combination of azacitidine (Aza) and venetoclax (Ven) is the standard treatment for older patients with acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy. Ven + Aza has been shown to increase complete remission rates and prolong overall survival. The current treatment regimen is based on the results of the VIALE-A study.